Overview
AKTS market data
Price History
AKTS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AKTS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33Benzinga · Jul 14, 2026, 1:43 PM
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 7, 2026, 2:05 PM
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For TuesdayBenzinga · Jun 16, 2026, 11:20 AM
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On FridayBenzinga · Jun 12, 2026, 2:15 PM
HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35Benzinga · Jun 2, 2026, 5:00 PM
Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 Radiopharmaceutical Data Presented At ASCO 2026Benzinga · May 21, 2026, 9:30 PM
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanyThe Motley Fool · May 13, 2026, 9:15 PM
8-K filing — Aktis Oncology, Inc. (AKTS)SEC EDGAR · May 11, 2026, 8:04 PM
Aktis Oncology to Present at the BofA Securities Health Care ConferenceGlobenewswire Inc · May 6, 2026, 12:10 PM